Dr. Perena Gouma's breathalyzer technology getting a lot of attention during COVID-19
Dr. Perena Gouma's research in breathalyzer testing is getting a lot of attention these days as her novel technology could be a simple, inexpensive and quick alternative to diagnosing COVID-19. Columbus television station, WBNS 10TV stopped by her lab for an interview which aired during their news broadcast on June 10.
She has developed a prototype that uses a mixture of gases to simulate the COVID-19 molecule. The gas is analyzed by a machine that operates like a breathalyzer by processing gases in a breath sample. 15 seconds later, results are ready with 90% accuracy. See the story aired by WBNS 10TV here.
A story about Dr. Gouma's technology was also covered by Ohio State's Chris Booker on June 5 (below).
Written and published by Chris Booker, Ohio State News, June 5
One of the most common COVID-19 tests involves a long swab pressed deep into the nasal cavities – and while the test can be administered quickly, it has been described as unpleasant and uncomfortable.
Now researchers at The Ohio State University are working on a testing system that would require a simple exhaled breath. Perena Gouma is the primary investigator of a team developing a breathalyzer device that will sample breath for key biomarkers of the infection. She says it would serve as an alternative to current tests that are expensive, can take a long time to get results and require specialized personnel to do the sampling and to analyze the results.
Gouma, director of the Advanced Ceramics Research Laboratory and professor in the College of Engineering, is working with co-investigator Andrew Bowman, associate professor of veterinary preventive medicine. The project was awarded a nearly $200,000 National Science Foundation EAGER grant this month under a program supporting exploratory, early-stage research on untested, but potentially transformative, ideas or approaches.
“Breath analysis is not really a technique that is used widely in the medical field yet, so it is considered early-stage work,” Gouma said. “[We] have a sensor device that detects nitric oxide and VOCs (volatile organic compounds) in breath and can be used to tell you about the onset of an infectious disease.”
In addition to nitric oxide, the device examines two other metabolites that could specifically indicate the presence of a COVID-19 infection even in asymptomatic patients. Exhaling once in the breathalyzer may help with earlier detection of the onset of the disease, as well as with monitoring of the severity of the infection, which could help reduce the risk for worsening of the symptoms and allow timely therapeutic intervention, she said.
The new project builds upon Gouma’s invention of a hand-held breath monitor that may provide early detection of flu before symptoms appear prior to her arrival at Ohio State. The COVID-19 breathalyzer involves advances on nanomaterials for detecting specific breath gases at the concentrations of interest for making a diagnosis.
The breathalyzer gives results rapidly (15 seconds response time), it is extremely inexpensive, and it is easy to use so that there is no need for trained personnel to perform the test, Gouma said. The results can be viewed directly on the display or they can be transferred to the physician wirelessly.
“We are working on making these hand-held monitors that will be widely distributed and they’re very inexpensive,” she said. “The technology evolved from the sensors used for monitoring gases in an automotive exhaust – that’s how we started on breath analysis 20 years ago.”
Gouma said the NSF-funded project would not have been possible without the collaboration with the College of Veterinary Medicine, the College of Medicine and the Wexner Medical Center. She said these connections make Ohio State very appealing for interdisciplinary research between engineering and medicine (nanomedicine).
“That’s one of the advantages of Ohio State. You don’t find many institutions that have the No. 1 vet med school in the world and also a world-class medical school,” she said. “It’s also serendipity because COVID-19 is a zoonosis, a disease that comes from animals, and the vet med school had years of experience studying coronaviruses and the flu in animals.”
Furthermore, the Wexner Medical Center has been treating COVID-19 patients from the beginning of the pandemic, so it offers unique insights to this project.
Gouma said the collaboration is critical for engineers developing medical diagnostics for humans and animals who need to consult with colleagues who have expertise in medicine to ensure that the ideas have merit and to validate their claims through clinical trials.
If the device proves to be accurate, portable and effective, it could be used to screen travelers before they step on a flight or to test students and teachers before they head back into the classroom. It would also be used in the Medical Intensive Care Units and in every hospital and doctor’s office as a bedside test. Gouma said the breathalyzer technology may become the platform to help detect metabolic problems like cancer, Alzheimer’s disease or diabetes, by choosing the appropriate biomarker to sample.